G8 Heiligendaam Summit Declaration on Growth and Responsibility in Africa

Sectors : International trade: market access, subsidies and aid for trade, Health systems, medicines and regulation, Health and technology, HIV/AIDS
Organisation : G8
Date made: 
You are viewing a filtered list of commitments, click here to view all commitments in this text

Commitments in: Health - HIV/AIDS

“57. The G8 reaffirm their commitment to scaling up towards “universal access” to comprehensive HIV prevention, treatment and care by 2010…We will therefore work with UNAIDS, WHO, WB and the GF to strengthen their efforts and work together with the African Union and African States, the innovative and generic pharmaceutical industry, private donors, civil society and other relevant stakeholders to help deliver next steps towards “universal access”…In particular we will work with:

African Governments

• to strengthen and finance health systems and make them more efficient with con-structive support of donors and the relevant international organizations such as WHO and World Bank,

• to contribute to the provision of affordable and quality medicines by eliminating or substantially reducing import tariffs and taxes with the aim to exempt price-reduced or subsidised medicines from these levies as soon as possible and examining logistics and governance issues that may hinder access,

• to strengthen procurement practices, ensuring accountability and transparency and to review the currently existing drug and device registration policies with the aim of facilitating timely access to safe, affordable and effective HIV/AIDS drugs and medical devices,

• to develop country-led policies that can ensure effective coordination of donor health programs and identify technical assistance needs, with the support of the WHO, World Bank, UNAIDS, GFATM and other agencies.

International Organizations and donors

• to support country-led efforts to improve coordination between all relevant stake-holders to develop costed, inclusive, sustainable, credible and evidence-based national AIDS plans which ensure effective links to health system strengthening,

• to intensify their efforts to assist countries in setting up a workable forecasting system for pharmaceutical demand,

• to respond constructively to requests by African developing countries without manufacturing capacities with regard to the use of the flexibilities referenced in the WTO Doha declaration on TRIPS and Public Health, while respecting WTO obligations,

• to continue to support investments in research and development of new medi-cines, microbicides and vaccines, including by promoting policies that encourage innovation.

The Pharmaceutical Industry

• to continue to explore further initiatives to provide enhanced access to HIV-medicines at affordable prices and to review price policies with regard to second-line antiretroviral drugs.

• to consider supporting local production of HIV/AIDS pharmaceuticals by voluntary licences and laboratory capacities that meet international standards and strengthen regulatory, certification and training institutes.

• to build on their expressed commitment to increase investment in research and development of new medicines, microbicides and vaccines also by extending public-private partnership.”